Skip to main content
. Author manuscript; available in PMC: 2011 May 27.
Published in final edited form as: Cancer Prev Res (Phila). 2009 Apr 28;2(5):440–449. doi: 10.1158/1940-6207.CAPR-08-0136

Table 5.

Baseline Ki67 levels

Observation Treated Difference (treated – observed)
Difference 95% CI P
All subjects
n 27 48
 Maximum 38.42 (24.28) 45.14 (26.65) 6.89 (−4.22 to 17.90) 0.22
 Average 18.51 (12.39) 21.82 (13.60) 3 41 (−2.04 to 8.85) 0.22
 Ki67 fraction 0.40 (0.35) 0.44 (0.31) 0.04 (−0.10 to 0.17) 0.59
Current smokers
n 12 21
 Maximum 53.17 (21.33) 57.29 (20.93) 4.12 (−11.43 to 19.08) 0.59
 Average 27.52 (10.53) 28.62 (13.20) 1.11 (−7.99 to 10.20) 0.81
 Ki67 fraction 0.06 (0.30) 0.59 (0.28) −0.06 (−0.27 to 0.14) 0.53
Former smokers
n 15 27
 Maximum 26.62 (20.04) 35.70 (27.12) 9.07 (−7.11 to 25.26) 0.26
 Average 11.31 (8.53) 16.54 (11.57) 5.23 (−1.68 to 12.13) 0.13
 Ki67 fraction 0.20 (0.25) 0.32 (0.28) 0.12 (−0.06 to 0.30) 0.19

NOTE: “All subject” analysis is adjusted for smoking status. Ki67 fraction is proportion of all samples within the individuals in which the Ki67 percentage exceeds 15%.